Back to Search
Start Over
Preclinical evaluation of188Re-HYNIC-PSMA as a novel therapeutic agent.
- Source :
-
Journal of Radioanalytical & Nuclear Chemistry . Feb2022, Vol. 331 Issue 2, p841-849. 9p. 1 Color Photograph, 1 Diagram, 8 Graphs. - Publication Year :
- 2022
-
Abstract
- In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. 188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 02365731
- Volume :
- 331
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Journal of Radioanalytical & Nuclear Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 155281259
- Full Text :
- https://doi.org/10.1007/s10967-021-08173-1